Dr. Mary Zupanc was a key investigator in a study that led to FDA approval for a medication to treat children with Dravet syndrome.
CHOC rare disease expert stresses importance of newborn screening
CHOC is one of the state’s largest referral centers for the newborn screening program, which checks babies for many serious genetic disorders.
Leading-edge biomarker research aids in infantile spasms management
Much of infantile spasms research focuses on visual analysis of a patient’s EEG, whereas Dr. Daniel Shrey’s research uses a computation.
How COVID-19 survivors can support others through plasma donation
It’s possible that the plasma of recovered COVID-19 patients may have antibodies that could help in the treatment of others with COVID-19.
Rapid genome testing for infants saves lives, costs
A recently completed pilot program at CHOC and other California clinical sites helped target a baby’s specific genetic disease in just days.
The forefront of CAR T-Cell immunotherapy research for high-risk pediatric leukemia patients
Along with providing access to clinical trials for CAR T-cell therapy and other immunotherapy, CHOC is a certified KYMRIAH treatment center.
